Pharming Group (NASDAQ:PHAR) Shares Down 8.8%

Pharming Group (NASDAQ:PHAR)’s stock price traded down 8.8% during trading on Friday . The company traded as low as $9.53 and last traded at $9.53. 1,241 shares were traded during trading, a decline of 52% from the average session volume of 2,603 shares. The stock had previously closed at $10.45.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Thursday, March 14th.

Pharming Group Trading Down 6.2 %

The firm has a market capitalization of $657.67 million, a PE ratio of -70.00 and a beta of 0.16. The stock’s 50-day moving average price is $10.83 and its 200 day moving average price is $11.42. The company has a debt-to-equity ratio of 0.62, a current ratio of 4.06 and a quick ratio of 3.33.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.08). The business had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $71.83 million. Pharming Group had a negative net margin of 4.13% and a negative return on equity of 4.53%. On average, sell-side analysts expect that Pharming Group will post -0.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Orion Portfolio Solutions LLC acquired a new stake in shares of Pharming Group (NASDAQ:PHAR) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,715 shares of the company’s stock, valued at approximately $134,000. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks.